Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9657448rdf:typepubmed:Citationlld:pubmed
pubmed-article:9657448lifeskim:mentionsumls-concept:C0037380lld:lifeskim
pubmed-article:9657448lifeskim:mentionsumls-concept:C0327519lld:lifeskim
pubmed-article:9657448lifeskim:mentionsumls-concept:C0009015lld:lifeskim
pubmed-article:9657448lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:9657448lifeskim:mentionsumls-concept:C0042479lld:lifeskim
pubmed-article:9657448lifeskim:mentionsumls-concept:C0006556lld:lifeskim
pubmed-article:9657448lifeskim:mentionsumls-concept:C1521991lld:lifeskim
pubmed-article:9657448lifeskim:mentionsumls-concept:C0086816lld:lifeskim
pubmed-article:9657448lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:9657448lifeskim:mentionsumls-concept:C0758147lld:lifeskim
pubmed-article:9657448pubmed:issue6lld:pubmed
pubmed-article:9657448pubmed:dateCreated1998-10-16lld:pubmed
pubmed-article:9657448pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:abstractTextThe entire cDNA sequences of a novel snake venom platelet glycoprotein (GP) Ib-binding protein (BP) composed of an alpha/beta heterodimeric structure, termed mamushigin, from Agkistrodon halys blomhoffii were determined, that include the leader peptides (21/23 amino acid residues) and mature subunits (136/123 amino acid residues). The mature subunits of mamushigin are 37.5% identical, and showed a high degree of similarity (37.7-67.5% identity) with the respective subunits of group VII C-type lectins (19). The sequences of the leader peptides of the mamusigin subunits showed the highest similarity (alpha-73.9/beta-82.6%) with those of factor IX/X-BP from Trimeresurus flavoviridis, and the cleavage site residue in both proteins was the same Ala(-1). The GPIb-binding specificity of mamushigin is strongly supported by several lines of evidence, but mamushigin can directly aggregate normal platelets, similar to alboaggregin-B (AL-B) (1). This differs from other GPIb-BP's. In mamushigin-treated platelets, serotonin was not released, and flow cytometric analysis using a monoclonal antibody PAC-1 totally excluded platelet GPIIb/IIIa activation. Mamushigin enhanced platelet aggregation at low-shear stress, and this effect totally disappeared in the presence of GPIb-receptor blockers specific for von Willebrand factor binding, but not by GPIIb/IIIa-receptor blockers. At high-shear stress, mamushigin blocked platelet aggregation in a dose-dependent manner, as seen with other GPIb-BP's. This paper, therefore, describes the cDNA cloning and molecular characterization of mamushigin which has a different effect on platelet aggregation under different shear stress.lld:pubmed
pubmed-article:9657448pubmed:languageenglld:pubmed
pubmed-article:9657448pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:citationSubsetIMlld:pubmed
pubmed-article:9657448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9657448pubmed:statusMEDLINElld:pubmed
pubmed-article:9657448pubmed:monthJunlld:pubmed
pubmed-article:9657448pubmed:issn0340-6245lld:pubmed
pubmed-article:9657448pubmed:authorpubmed-author:ImamuraKKlld:pubmed
pubmed-article:9657448pubmed:authorpubmed-author:SuzukiMMlld:pubmed
pubmed-article:9657448pubmed:authorpubmed-author:KawasakiTTlld:pubmed
pubmed-article:9657448pubmed:authorpubmed-author:SakuraiYYlld:pubmed
pubmed-article:9657448pubmed:authorpubmed-author:MatsuiTTlld:pubmed
pubmed-article:9657448pubmed:authorpubmed-author:FujimuraYYlld:pubmed
pubmed-article:9657448pubmed:authorpubmed-author:YoshiokaAAlld:pubmed
pubmed-article:9657448pubmed:authorpubmed-author:TitaniKKlld:pubmed
pubmed-article:9657448pubmed:authorpubmed-author:KokuboTTlld:pubmed
pubmed-article:9657448pubmed:authorpubmed-author:HandaMMlld:pubmed
pubmed-article:9657448pubmed:issnTypePrintlld:pubmed
pubmed-article:9657448pubmed:volume79lld:pubmed
pubmed-article:9657448pubmed:ownerNLMlld:pubmed
pubmed-article:9657448pubmed:authorsCompleteYlld:pubmed
pubmed-article:9657448pubmed:pagination1199-207lld:pubmed
pubmed-article:9657448pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:meshHeadingpubmed-meshheading:9657448-...lld:pubmed
pubmed-article:9657448pubmed:year1998lld:pubmed
pubmed-article:9657448pubmed:articleTitleThe cDNA cloning and molecular characterization of a snake venom platelet glycoprotein Ib-binding protein, mamushigin, from Agkistrodon halys blomhoffii venom.lld:pubmed
pubmed-article:9657448pubmed:affiliationDepartment of Pediatrics and Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan.lld:pubmed
pubmed-article:9657448pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9657448pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9657448pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9657448lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9657448lld:pubmed